Movement Disorders, Parkinson's Disease
Dyskinesia – Advances in the Understanding of Pathophysiology and Possible Treatment Options
Hanna S Lindgren, M Angela Cenci, Emma L Lane
Since its introduction in the 1960s, dopamine replacement therapy with its metabolic precursor L-3,4-dihydroxyphenylanaline (L-DOPA) has remained the most effective pharmacotherapy for Parkinson’s disease (PD).1 Particularly in early disease, it is efficiently converted into dopamine, replacing that which is lost through the degeneration of nigrostriatal dopaminergic neurons. In doing so, L-DOPA alleviates bradykinesia and rigidity, […]